10x Genomics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Royal Bank of Canada (RY-T) led Q3 share buybacks with $2.3B, followed by Bank of Montreal (BMO-T) and Canadian Natural Resources (CNQ-T). Insider buying was absent in these top buybacks. Zodiac Gold (TXG-T) saw a 40.9% rally since July, with $117.4M in buybacks and insider buying. Other companies with buybacks and insider activity include Nutrien (NTR-T), Trican Well Service (TCW-T), and Rockpoint Gas Storage (RGSI-T).
10x Genomics scheduled a public call on Nov. 5 to discuss its third-quarter 2026 financial results. The live webcast will be available on the company's investor relations website and archived for 45 days. 10x Genomics is a life science technology company focused on single cell and spatial biology research solutions.
TD Cowen raised its price target for 10X Genomics (NASDAQ:TXG) to $70 from $47, citing increased revenue estimates and growth in Atera sales. The stock has gained 548% over the past year. Analysts have mixed views on the company's future, with some highlighting strong demand for Atera and others expressing caution. 10X Genomics reported Q2 2026 revenue of $151.04 million, beating estimates.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning TXG (10x Genomics, Inc.). Coverage has been balanced: 3 bullish, 1 neutral, and 3 bearish.
Recent TXG coverage spans financial news, market movers and earnings.
In the last 30 days, TXG insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($2.5M). The most active reporter was SULIMAN SHEHNAAZ with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider buying plus repurchases supports the article’s bullish setup, though the stock’s prior run may already price some optimism.
The announcement provides the timing of the earnings release but contains no new financial data.
Analyst upgrade suggests bullish sentiment and may drive buying pressure.
Street targets skew higher for TXG, supporting incremental upside bias versus prior expectations.
The stock is under pressure from stretched valuation, insider sell‑off and weak fundamentals, likely prompting further downside.
AlphAI scores every news story that mentions TXG with an AI model for sentiment and relevance, and aggregates insider trades from 10x Genomics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Royal Bank of Canada (RY-T) led Q3 share buybacks with $2.3B, followed by Bank of Montreal (BMO-T) and Canadian Natural Resources (CNQ-T). Insider buying was absent in these top buybacks. Zodiac Gold (TXG-T) saw a 40.9% rally since July, with $117.4M in buybacks and insider buying. Other companies with buybacks and insider activity include Nutrien (NTR-T), Trican Well Service (TCW-T), and Rockpoint Gas Storage (RGSI-T).
7 min read10x Genomics scheduled a public call on Nov. 5 to discuss its third-quarter 2026 financial results. The live webcast will be available on the company's investor relations website and archived for 45 days. 10x Genomics is a life science technology company focused on single cell and spatial biology research solutions.
1 min readTD Cowen raised its price target for 10X Genomics (NASDAQ:TXG) to $70 from $47, citing increased revenue estimates and growth in Atera sales. The stock has gained 548% over the past year. Analysts have mixed views on the company's future, with some highlighting strong demand for Atera and others expressing caution. 10X Genomics reported Q2 2026 revenue of $151.04 million, beating estimates.
2 min readU.S. analyst updates on October 12th, 2026, show a cautious outlook with more price-target reductions than increases. Financials, insurance, and real estate saw conservative valuations, while tech sentiment was mixed. Energy received stronger support, and healthcare saw positive coverage.
6 min read10X Genomics (TXG) shares fell 10.3% to $72.33 amid volatility and valuation reassessment. Canaccord Genuity raised its price target to $100, but analysts' consensus remains 'Hold' with a $58.60 average target. Insider selling and declining revenue add pressure. The stock has been volatile, dropping 13.4% and 6.2% on Oct. 6 and 8, respectively.
2 min read15 analysts raised the 12-month price target for 10x Genomics (TXG) from $72.13 to $74.13, with a range of $47 to $110. This implies an 8% downside from the Oct. 9 closing price. The consensus rating remains 'Buy' among 18 analysts, with 6 Buys, 11 Holds, and 1 Sell.
1 min read10x Genomics (TXG) shares rose 6.1% after Bank of America raised its price target to $80 from $50, citing improved sentiment and consumables revenue growth. The firm maintained a Neutral rating, noting hardware revenue volatility and operating losses. TXG is up 391% year-to-date but trades 16.5% below its 52-week high.
1 min read10x Genomics announced commercial shipments of its Atera spatial biology platform and early access to the Sentira cloud analysis suite. The company also partnered with Fred Hutchinson Cancer Center to expand its oncology research. Analysts project $780.7M revenue and $125M earnings by 2029, but note risks including funding pressure and execution challenges. Sentira's early access phase is key to the company's strategy.
3 min read10x Genomics (NASDAQ:TXG) partners with Fred Hutch on cancer research, using its platforms to study bladder cancer and leukemia. The collaboration aims to advance single cell and spatial technologies in cancer treatment and monitoring, marking 10x's first clinical research initiative in blood cancers. The company plans to develop a framework for clinical reporting and supports its CLIA-certified lab efforts for future diagnostic applications.
1 min readPacific Biosciences (PACB), Fortrea (FTRE), Alamar (ALMR), 10x Genomics (TXG), and Azenta (AZTA) reached 52-week highs on October 6, 2026. PACB announced a collaboration with TychoBio, FTRE reported Q2 revenue of $678M, ALMR saw Q2 revenue surge to $29.43M, TXG launched the Atera platform, and AZTA reported 12% Q3 revenue growth.
2 min read
